Methods for inhibiting osteoclastogenesis
OwnerSuzanne Lentzschinventor
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of osteolytic bone disease and for the inhibition of osteoclastogenesis are disclosed. The methods utilize COX-2 inhibitors and/or inhibitors of NF-κB activation, administered to patients in an amount effective to inhibit osteoclastogenesis. Also disclosed are methods to modulate the expression of MIP-1α in a subject.
Claims24
A method for treating osteolytic bone disease in a subject in need of such treatment, comprising administering to the subject a composition comprising a pharmaceutically acceptable carrier and at least one cyclooxygenase-2 (COX-2) inhibitor in an amount effective to treat osteolytic bone disease in the subject.
A method for treating osteolytic bone disease in a subject in need of such treatment, comprising administering to the subject a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of NF-κB activation in an amount effective to treat osteolytic bone disease in the subject.
A method for inhibiting osteoclastogenesis in a subject comprising administering to the subject a composition comprising a pharmaceutically acceptable carrier and at least one COX-2 inhibitor in an amount effective to inhibit osteoclastogenesis in the subject.
A method of inhibiting MIP-1α in a subject comprising administering to the subject a composition comprising a pharmaceutically acceptable carrier and at least one cyclooxygenase-2 (COX-2) inhibitor in an amount effective to inhibit MIP-1α expression in the subject.
A method for inhibiting osteoclastogenesis in a subject comprising administering to the subject a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of NF-κB activation in an amount effective to inhibit osteoclastogenesis in the subject.
Dependencies are inferred from the claim text.